James Healy bought $12.0M of BioAge Labs (BIOA)
Executed Sep 27 2024, disclosed Sep 27 2024, the same day.
Over the 21 trading sessions from the disclosed entry session (Sep 27 2024), the stock returned +24.7% (delay-adjusted); from the execution session (Sep 27 2024), +24.7%. Derived: entry at the session's open, exit at the close 20 sessions later.
James Healy (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in BioAge Labs, Inc. (BIOA). Across 1 priced purchase filing, the average 21-session return was +24.7% from execution and +24.7% from disclosure (delay-adjusted; derived). The largest single filing was $12.0M of BIOA (666,665 sh across 5 lots, as filed), executed Sep 27 2024.
Healthcare · BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→